Compare BTDR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | TSHA |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | BTDR | TSHA |
|---|---|---|
| Price | $5.67 | $4.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $20.92 | $13.00 |
| AVG Volume (30 Days) | ★ 10.1M | 3.2M |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $54.56 | N/A |
| Revenue Next Year | $70.16 | $783.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $5.03 | $3.46 |
| 52 Week High | $20.72 | $7.30 |
| Indicator | BTDR | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 43.88 |
| Support Level | $5.03 | $3.92 |
| Resistance Level | $13.15 | $4.59 |
| Average True Range (ATR) | 0.73 | 0.29 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 19.28 | 24.59 |
Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.